BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19813275)

  • 21. Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study.
    Katzenstein HM; Malogolowkin MH; Krailo MD; Piao J; Towbin AJ; McCarville MB; Tiao GM; Dunn SP; Langham MR; McGahren ED; Finegold MJ; Ranganathan S; Weldon CB; Thompson PA; Trobaugh-Lotrario AD; O'Neill AF; Furman WL; Chung N; Randazzo J; Rodriguez-Galindo C; Meyers RL
    Cancer; 2022 Mar; 128(5):1057-1065. PubMed ID: 34762296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology.
    von Schweinitz D; Byrd DJ; Hecker H; Weinel P; Bode U; Bürger D; Erttmann R; Harms D; Mildenberger H
    Eur J Cancer; 1997 Jul; 33(8):1243-9. PubMed ID: 9301450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
    Gallegos-Castorena S; Martínez-Avalos A; Mohar-Betancourt A; Guerrero-Avendaño G; Zapata-Tarrés M; Medina-Sansón A
    Pediatr Hematol Oncol; 2007 Sep; 24(6):403-8. PubMed ID: 17710657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined carboplatin and cisplatin. Limited prospects for dose intensification.
    Waterhouse DM; Reynolds RK; Natale RB
    Cancer; 1993 Jun; 71(12):4060-6. PubMed ID: 8508371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
    Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
    Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee.
    Katzenstein HM; Furman WL; Malogolowkin MH; Krailo MD; McCarville MB; Towbin AJ; Tiao GM; Finegold MJ; Ranganathan S; Dunn SP; Langham MR; McGahren ED; Rodriguez-Galindo C; Meyers RL
    Cancer; 2017 Jun; 123(12):2360-2367. PubMed ID: 28211941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Redefining the role of doxorubicin for the treatment of children with hepatoblastoma.
    Malogolowkin MH; Katzenstein HM; Krailo M; Chen Z; Quinn JJ; Reynolds M; Ortega JA
    J Clin Oncol; 2008 May; 26(14):2379-83. PubMed ID: 18467729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor.
    Rick O; Beyer J; Schwella N; Schubart H; Schleicher J; Siegert W
    Ann Oncol; 2001 Aug; 12(8):1151-5. PubMed ID: 11583199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2.
    Perilongo G; Shafford E; Maibach R; Aronson D; Brugières L; Brock P; Childs M; Czauderna P; MacKinlay G; Otte JB; Pritchard J; Rondelli R; Scopinaro M; Staalman C; Plaschkes J;
    Eur J Cancer; 2004 Feb; 40(3):411-21. PubMed ID: 14746860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Altmann S; Hoffmanns H
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
    Tannehill SP; Mehta MP; Larson M; Storer B; Pellet J; Kinsella TJ; Schiller JH
    J Clin Oncol; 1997 Aug; 15(8):2850-7. PubMed ID: 9256128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer.
    Han HS; Han JY; Yu SY; Pyo HR; Kim HY; Cho KH; Lee DH; Kim HT; Lee JS
    Cancer; 2008 Oct; 113(7):1623-31. PubMed ID: 18671241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
    Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current chemotherapeutic approaches for hepatoblastoma.
    Watanabe K
    Int J Clin Oncol; 2013 Dec; 18(6):955-61. PubMed ID: 24052132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens.
    Dean JB; Hayashi SS; Albert CM; King AA; Karzon R; Hayashi RJ
    J Pediatr Hematol Oncol; 2008 Feb; 30(2):130-4. PubMed ID: 18376265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
    Betticher DC; Anderson H; Ranson M; Meely K; Oster W; Thatcher N
    Br J Cancer; 1995 Dec; 72(6):1551-5. PubMed ID: 8519676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study.
    Kanat O; Evrensel T; Baran I; Coskun H; Zarifoglu M; Turan OF; Kurt E; Demiray M; Gonullu G; Manavoglu O
    Med Oncol; 2003; 20(3):237-45. PubMed ID: 14514973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
    Kemp G; Rose P; Lurain J; Berman M; Manetta A; Roullet B; Homesley H; Belpomme D; Glick J
    J Clin Oncol; 1996 Jul; 14(7):2101-12. PubMed ID: 8683243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group.
    Malogolowkin MH; Katzenstein HM; Meyers RL; Krailo MD; Rowland JM; Haas J; Finegold MJ
    J Clin Oncol; 2011 Aug; 29(24):3301-6. PubMed ID: 21768450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer.
    Antonadou D; Throuvalas N; Petridis A; Bolanos N; Sagriotis A; Synodinou M
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):402-8. PubMed ID: 12957251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.